30930802|t|Intellectual Disability Associated With Pyridoxine-Responsive Epilepsies: The Need to Protect Cognitive Development.
30930802|a|Pyridoxine (vitamin B6)-responsive epilepsies are severe forms of epilepsy that manifest as seizures immediately after birth, sometimes in utero, sometimes months, or years after birth. Seizures may be treated efficiently by life-long supplementation with pyridoxine or its biologically active form, pyridoxal phosphate, but even so patients may become intellectually disabled, for which there currently is no effective treatment. The condition may be caused by mutations in several genes (TNSALP, PIGV, PIGL, PIGO, PNPO, PROSC, ALDH7A1, MOCS2, or ALDH4A1). Mutations in ALDH7A1, MOCS2, and ALDH4A1 entail build-up of reactive aldehydes (alpha-aminoadipic semialdehyde, gamma-glutamic semialdehyde) that may react non-enzymatically with macromolecules of brain cells. Such reactions may alter the function of macromolecules, and they may produce "advanced glycation end products" (AGEs). AGEs trigger inflammation in the brain. This understanding points to aldehyde-quenching, anti-AGE, or anti-inflammatory therapies as possible strategies to protect cognitive development and prevent intellectual disability in affected children. Studies on how aldehydes traverse cell membranes and how they affect brain function could further the development of therapies for patients with pyridoxine-responsive epilepsies.
30930802	0	23	Intellectual Disability	Disease	MESH:D008607
30930802	40	50	Pyridoxine	Chemical	MESH:D011736
30930802	62	72	Epilepsies	Disease	MESH:D004827
30930802	117	127	Pyridoxine	Chemical	MESH:D011736
30930802	129	139	vitamin B6	Chemical	MESH:D025101
30930802	152	162	epilepsies	Disease	MESH:D004827
30930802	183	191	epilepsy	Disease	MESH:D004827
30930802	209	217	seizures	Disease	MESH:D012640
30930802	303	311	Seizures	Disease	MESH:D012640
30930802	373	383	pyridoxine	Chemical	MESH:D011736
30930802	417	436	pyridoxal phosphate	Chemical	MESH:D011732
30930802	450	458	patients	Species	9606
30930802	470	493	intellectually disabled	Disease	MESH:D008607
30930802	607	613	TNSALP	Gene	249
30930802	615	619	PIGV	Gene	55650
30930802	621	625	PIGL	Gene	9487
30930802	627	631	PIGO	Gene	84720
30930802	633	637	PNPO	Gene	55163
30930802	639	644	PROSC	Gene	11212
30930802	646	653	ALDH7A1	Gene	501
30930802	655	660	MOCS2	Gene	4338
30930802	665	672	ALDH4A1	Gene	8659
30930802	688	695	ALDH7A1	Gene	501
30930802	697	702	MOCS2	Gene	4338
30930802	708	715	ALDH4A1	Gene	8659
30930802	744	753	aldehydes	Chemical	MESH:D000447
30930802	755	785	alpha-aminoadipic semialdehyde	Chemical	MESH:C000061
30930802	787	814	gamma-glutamic semialdehyde	Chemical	-
30930802	1018	1030	inflammation	Disease	MESH:D007249
30930802	1074	1082	aldehyde	Chemical	MESH:D000447
30930802	1099	1102	AGE	Disease	OMIM:613784
30930802	1112	1124	inflammatory	Disease	MESH:D007249
30930802	1203	1226	intellectual disability	Disease	MESH:D008607
30930802	1264	1273	aldehydes	Chemical	MESH:D000447
30930802	1380	1388	patients	Species	9606
30930802	1394	1404	pyridoxine	Chemical	MESH:D011736
30930802	1416	1426	epilepsies	Disease	MESH:D004827
30930802	Association	MESH:D000447	501
30930802	Association	MESH:C000061	4338
30930802	Negative_Correlation	MESH:D011732	MESH:D012640
30930802	Negative_Correlation	MESH:D025101	MESH:D004827
30930802	Negative_Correlation	MESH:D000447	MESH:D008607
30930802	Positive_Correlation	MESH:D025101	MESH:D012640
30930802	Association	MESH:D000447	8659
30930802	Negative_Correlation	MESH:D011736	MESH:D004827
30930802	Negative_Correlation	MESH:D011736	MESH:D012640
30930802	Association	MESH:D000447	4338
30930802	Association	MESH:C000061	501
30930802	Association	MESH:C000061	8659
30930802	Positive_Correlation	MESH:D011736	MESH:D008607

